Get started
Author

H. Tezcan

Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP).
2010 · A. L. Cohn, T. Bekaii-Saab, et al. · Journal of Clinical Oncology · 53
Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation
1999 · J Schriber, B Milk, et al. · Bone Marrow Transplantation · 32
Severe cerebellar swelling and thrombotic thrombocytopenic purpura associated with FK506
1998 · H Tezcan, W Zimmer, et al. · Bone Marrow Transplantation · 28
Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, an observational cohort study (OCS).
2011 · M. Kozloff, T. S. Bekaii-Saab, et al. · Journal of Clinical Oncology · 17
Similarities in treatment (Tx) patterns and clinical outcomes (CO) in patients (pts) with metastatic colorectal cancer (mCRC) initially treated with FOLFOX/BV or FOLFIRI/BV: Results from ARIES, a bevacizumab (BV) observational study.
2011 · J. C. Bendell, T. S. Bekaii-Saab, et al. · Journal of Clinical Oncology · 9
Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases.
1994 · A Z Tezcan, H Tezcan, et al. · PubMed · 9
Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS).
2010 · T. S. Bekaii-Saab, J. C. Bendell, et al. · Journal of Clinical Oncology · 8
Initial results from ARIES, a multi-indication bevacizumab (BV) observational cohort study (OCS): Characteristics of metastatic colorectal cancer (mCRC) patients (pts) receiving BV and chemotherapy (CT) in 2nd line
2008 · T. S. Bekaii-Saab, J. C. Bendell, et al. · Journal of Clinical Oncology · 5
Comparison of enzymatic-and bisulfite conversion to map the plasma cell-free methylome in cancer
2019 · N. Lambert, A. Robertson, et al. · Annals of Oncology · 4
Longitudinal changes in cell-free DNA (cfDNA) methylation levels identify early non-responders to treatment in advanced solid tumours
2019 · A.A. Davis, W. Iams, et al. · Annals of Oncology · 1
PDF
P1.01-49 Serial Changes in Whole-Genome Cell-Free DNA (cfDNA) to Identify Disease Progression Prior to Imaging in Advanced NSCLC
2019 · A. Davis, W. Iams, et al. · Journal of Thoracic Oncology · 1
PDF
P1-18-01: Z-ACT1: Zometa Combined with Standard Therapy in Patients with Metastatic Breast Cancer Further Decreases the Proportion of Patients with CTC Counts of 5 or above.
2011 · A Brufsky, J Beck, et al. · Cancer Research · 1
Treatment of Acute Promyelocytic Leukemia in Patients Presenting at Vancouver General Hospital from 1983 to 1992
1995 · H. Tezcan, M. J. Barnett, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 1
179P Developing the AI program for TNBC subtyping
2023 · E. Bulut, R.F. Balaban, et al. · ESMO Open
PDF
Dynamic changes in whole-genome cell-free DNA (cfDNA) to identify disease progression prior to imaging in advanced solid tumours
2019 · A.A. Davis, W. Iams, et al. · Annals of Oncology
EP1.01-94 The Role of Neoadjuvant Chemo-Immunotherapy in Unresectable Non-Small Cell Lung Cancer
2019 · M. Oh, A. Davis, et al. · Journal of Thoracic Oncology
Works count: 16
Citation count: 169
H-index: 7
I10-index: 4
Year
Topic
Type